Vericel (FRA:ATQP) FFO


FRA:ATQP Vericel Corp FRA:ATQP
75 GF Score
Price €37.00
GF Value €43.45
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Vericel FFO?

FFO (Funds from operations) only applies to REITs.

FRA:ATQP
75GF Score
Vericel Corp FRA:ATQP
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Vericel (FRA:ATQP) Overvalued in 2026?

Based on GuruFocus' analysis, Vericel stock appears to be undervalued. The current stock price of €37.00 is trading 14.8% below its estimated GF Value™ of €43.45. GuruFocus considers Vericel to be Modestly Undervalued.

Key valuation signals for FRA:ATQP:

  • FFO:
  • GF Value™: €43.45 vs. price of €37.00 (14.8% below fair value)
  • GF Score™: 75/100 with 7 warning signs

No single metric tells the full story. See the FRA:ATQP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vericel Business Description

Other Exchanges VCEL:USA
Address 64 Sidney Street, Cambridge, MA, USA, 02139
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
75GF Score

Get the complete analysis for FRA:ATQP

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€37.00
Price
€43.45
GF Value